Loading...
Intas Pharmaceuticals Limited — Azathioprine Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #10 for Azathioprine · $97.9K export value · DGFT Verified
Intas Pharmaceuticals Limited is the #10 Indian exporter of Azathioprine with $97.9K in export value and 3 verified shipments. Intas Pharmaceuticals Limited holds a 0.3% market share in Azathioprine exports across 1 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $8.4M | 169 | 41.2% |
| GERMANY | $3.5M | 161 | 17.0% |
| UNITED KINGDOM | $3.3M | 71 | 16.0% |
| CANADA | $1.1M | 23 | 5.6% |
| COLOMBIA | $737.9K | 18 | 3.6% |
| FRANCE | $650.0K | 13 | 3.2% |
| AUSTRALIA | $611.2K | 16 | 3.0% |
| CHILE | $550.0K | 11 | 2.7% |
| EGYPT | $431.2K | 10 | 2.1% |
| NETHERLANDS | $345.8K | 20 | 1.7% |
India exports Azathioprine to 68 countries. The top destination is UNITED STATES (41.2%), followed by GERMANY and UNITED KINGDOM.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCE SERVICES | UNITED STATES | $5.2M | 104 |
| AQVIDA GMBH | GERMANY | $3.3M | 154 |
| AMNEAL PHARMACEUTICALS, LLC (KY) | UNITED STATES | $1.7M | 34 |
| TILLOMED LABORATORIES LTD. | UNITED KINGDOM | $728.6K | 18 |
| TILLOMED LABORATORIES LIMITED. |
India exported $23.0M worth of Azathioprine through 886 shipments from 134 suppliers to 68 countries, serving 203 buyers globally. Intas Pharmaceuticals Limited contributes $97.9K to this total, accounting for 0.3% of India's Azathioprine exports.
Intas Pharmaceuticals Limited's average Azathioprine shipment value is $32.6K per consignment, based on 3 shipments totaling $97.9K.
Intas Pharmaceuticals Limited ranks #10 among 134 Indian Azathioprine exporters with a 0.3% market share. The top 3 exporters are RPG LIFE SCIENCES LIMITED ($12.1M), ZYDUS LIFESCIENCES LIMITED ($5.1M), AMNEAL PHARMACEUTICALS PRIVATE LIMITED ($3.0M). Intas Pharmaceuticals Limited processed 3 shipments to 1 destination countries.
What Intas Pharmaceuticals Limited must comply with to export Azathioprine to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 6 | EMCURE PHARMACEUTICALS LIMITED | $150.0K | 3 | 1 | $50.0K |
| 9 | STRIDES PHARMA SCIENCE LIMITED | $137.7K | 5 | 1 | $27.5K |
| 10 | INTAS PHARMACEUTICALS LIMITED ★ | $97.9K | 3 | 1 | $32.6K |
| 11 | CENTURION HEALTHCARE PRIVATE LIMITED | $93.1K | 3 | 1 | $31.0K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 162 | 18.3% |
| SAHAR AIR | 130 | 14.7% |
| MUNDRA SEA | 80 | 9.0% |
| NHAVA SHEVA SEA (INNSA1) | 79 | 8.9% |
| DELHI AIR | 44 | 5.0% |
| Bombay Air | 39 | 4.4% |
| MUNDRA SEA (INMUN1) | 38 | 4.3% |
| DELHI AIR CARGO ACC (INDEL4) | 38 | 4.3% |
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Azathioprine, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Azathioprine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Azathioprine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
| UNITED KINGDOM |
| $700.0K |
| 14 |
| AMNEAL PHARMACEUTICALS LLC (KY) | UNITED STATES | $650.0K | 13 |
| APOTEX INC. | CANADA | $600.0K | 12 |
| ELARA PHARMASERVICES LTD | UNITED KINGDOM | $600.0K | 12 |
| APOTEX INC | CANADA | $550.0K | 11 |
| AMNEAL PHARMACEUTICALS LLC KY | UNITED STATES | $550.0K | 11 |
India's Azathioprine is purchased by 203 buyers worldwide. The top buyer is EVERSANA LIFE SCIENCE SERVICES (UNITED STATES), followed by AQVIDA GMBH and AMNEAL PHARMACEUTICALS, LLC (KY).
Marketing Authorisation via Decentralized or Mutual Recognition Procedure under EU Directive 2001/83/EC. CTD Module 1–5 dossier required.
Timeline: 12–18 months via Decentralized Procedure
GMP & Export Requirements
EU GMP (EudraLex Vol. 4); GMP certificate from EU competent authority; WHO Prequalification accepted as supporting evidence
Certificate of Pharmaceutical Product (CPP) from CDSCO; Written Confirmation for API export per EU requirements; EU FMD serialization mandatory
Note: Indian manufacturers must hold EU GMP certificate. EU Falsified Medicines Directive (FMD) serialization and tamper-evident packaging mandatory.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 12 |
| UNICURE REMEDIES PRIVATE LIMITED |
| $45.8K |
| 6 |
| 3 |
| $7.6K |
Intas Pharmaceuticals Limited ranks #10 among 134 Indian Azathioprine exporters. Average shipment value of $32.6K compared to the market average of $171.8K. The closest competitors by value are EMCURE PHARMACEUTICALS LIMITED and STRIDES PHARMA SCIENCE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 68+ countries, 203+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Azathioprine. For current shipment-level data, contact TransData Nexus.